{
    "clinical_study": {
        "@rank": "73919", 
        "arm_group": [
            {
                "arm_group_label": "Oraxol Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "HM30181AK-US tablet administered as a single oral dose of 15 mg on Days 1, 8, and 15 of each cycle\nPaclitaxel administered as a fixed oral daily dose of 270 mg (nine 30 mg capsules) starting on Days 1, 8, and 15 of each cycle.  Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
            }, 
            {
                "arm_group_label": "Oraxol Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "HM30181AK-US tablet administered as a single oral dose of 15 mg daily with each dose of Paclitaxel\nPaclitaxel administered as a fixed oral daily dose of 270 mg (nine 30 mg capsules) starting on Days 1, 8, and 15 of each cycle.  Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a standard \"3+3\" Phase 1b study to determine the MTD of Oraxol (paclitaxel + HM30181\n      Methanesulfonate monohydrate) in subjects with advanced malignancies that may be metastatic\n      or unresectable with measurable malignant lesion(s) per RECIST Version 1.1 criteria."
        }, 
        "brief_title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent\n\n          2. \u2265 18 years of age\n\n          3. Histologically or cytologically confirmed solid tumor that is metastatic or\n             unresectable and for which standard curative or palliative measures do not exist or\n             are no longer effective.\n\n          4. Measurable disease as per RECIST Version 1.1 criteria.\n\n          5. Adequate bone marrow reserve as demonstrated by\n\n               -  Absolute neutrophil count (ANC) \u22651.5 x 10\u2079/L\n\n               -  Platelet count \u2265 100 x 10\u2079/L\n\n               -  Hemoglobin (Hgb) \u2265 9 g/L\n\n          6. Adequate liver function as demonstrated by\n\n               -  Total bilirubin of \u2264 1.5 mg/dL or \u2264 2.0 mg/dL for subjects with liver metastasis\n\n               -  Alanine aminotransferase (ALT)\u2264 3 x upper limit of normal (ULN)  or \u2264 5x ULN if\n                  liver metastasis is present\n\n               -  ALP \u2264 3 x ULN  or \u2264 5 x ULN if bone metastasis is present\n\n          7. Adequate renal function as demonstrated by serum creatinine \u2264  1.5 x ULN, or 24-hr\n             urine creatinine clearance calculation >60 mL/min\n\n          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n\n          9. Life expectancy of at least 3 months\n\n         10. Subjects who are not currently taking a medication known to be clinically significant\n             P-gp inhibitors or inducers. Subjects who are taking such medications but who are\n             otherwise eligible may be enrolled if they discontinue the medication 1 week before\n             dosing and remain off that medication during treatment with Oraxol.\n\n         11. Subjects who are not currently taking a medication known to be clinically significant\n             inhibitors (gemfibrozil) or inducers (rifampin) of CYP2C8\n\n         12. Women must be postmenopausal (> 12 months without menses) or surgically sterile (ie,\n             by hysterectomy and/or bilateral oophorectomy) or must be using effective\n             contraception\n\n         13. Subjects who are not currently taking a medication known to be strong inhibitors or\n             inducers of CYP3A4.\n\n         14. Subjects who are not currently taking a medication known to be P-gp substrate.\n\n        Exclusion Criteria:\n\n          1. Have not recovered to \u2264 Grade 1 toxicity from previous anticancer treatments or\n             previous investigational agents\n\n          2. Received investigational agents within 14 days or 5 half-lives of the first study\n             dosing day, whichever is longer.\n\n          3. Women of childbearing potential who are pregnant or breast feeding.\n\n          4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, myocardial infarction within the\n             last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary\n             disease requiring oxygen, known bleeding disorders, or psychiatric illness/social\n             situations that would limit compliance with study requirements\n\n          5. Significant or uncontrolled cardiovascular disease or bleeding disorder\n\n          6. Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI\n             disease or other medical condition that, in the opinion of the investigator may\n             interfere with oral drug absorption\n\n          7. Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was\n             due to the IV solvent (such as Cremophor\u00ae) and not paclitaxel will be eligible for\n             this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967043", 
            "org_study_id": "ORAX-01-13-US"
        }, 
        "intervention": {
            "arm_group_label": [
                "Oraxol Arm 1", 
                "Oraxol Arm 2"
            ], 
            "description": "Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.", 
            "intervention_name": "Oraxol", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "800045"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Antonio Jimeno, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "Nilofer Azad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Wen Wee Ma, MBBS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies", 
        "overall_contact": {
            "email": "jgoldfinch@kinexpharma.com", 
            "last_name": "John Goldfinch, MBA, CRM", 
            "phone": "7168988629"
        }, 
        "overall_official": {
            "affiliation": "Kinex Pharmaceuticals Inc", 
            "last_name": "Min-Fun Rudolf Kwan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the maximum tolerated dose (MTD) of Oraxol in subjects with advanced malignancies", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967043"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To determine the recommended Phase 2 dose (RP2D) of Oraxol", 
            "safety_issue": "No", 
            "time_frame": "one year six months"
        }, 
        "source": "Kinex Pharmaceuticals Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Atlantic Research Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Kinex Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}